The Development of Transfusion-Related Acute Lung Injury for the Second Time: A New Awareness for Daratumumab?. (September 2021)

• Record Type: Journal Article
• Authors: Turgutkaya, Atakan; Bolaman, Ali Zahit; Yavaşoğlu, İrfan
• Is Part Of: Plasmatology. Volume 15(2021)
• Publication Date: 2021-09
• Subjects: acute lung injury -- comorbidity -- endothelium -- multiple myeloma -- neutrophils; Blood plasma -- Periodicals; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 612.116
• DOI: 10.1177/26348535211038276
• Languages: English
• ISSNs: 2634-8535

Abstract

Transfusion-related acute lung injury (TRALI) is an undesired and potentially fatal complication of blood transfusion. Besides human neutrophil and leukocyte antigens of the donor blood; especially for red blood cell transfusions, nonantibody-mediated mechanisms seem responsible. Among these patients, pulmonary neutrophils have increased sensitivity to initiate TRALI. It is a very rare event for a patient to develop a second reaction. Comorbid conditions such as kidney failure and cardiovascular diseases may pose a risk. Daratumumab, an anti-CD38 monoclonal antibody, seems unrelated because it only causes indirect Coombs positivity without triggering transfusion complications. However, its role in recipient–donor interactions causing TRALI is less clear. Here, we report a relapsed multiple myeloma-diagnosed patient who developed TRALI under daratumumab treatment.